- Home
- ROIV vs AVB Comparison
ROIV vs AVB Comparison
Compare ROIV & AVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | AVB |
|---|---|---|
| Founded | 2014 | 1978 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2B | 27.8B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ROIV | AVB |
|---|---|---|
| Price | $35.36 | $182.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 15 |
| Target Price | $28.94 | ★ $198.40 |
| AVG Volume (30 Days) | ★ 4.8M | 685.1K |
| Earning Date | 05-28-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 3.86% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 3.43 |
| Revenue | $8,260,000.00 | ★ $3,040,725,000.00 |
| Revenue This Year | N/A | $4.04 |
| Revenue Next Year | $744.61 | $5.03 |
| P/E Ratio | ★ N/A | $53.52 |
| Revenue Growth | N/A | ★ 4.36 |
| 52 Week Low | $11.54 | $160.10 |
| 52 Week High | $37.00 | $198.63 |
Technical Indicators
Market Signals| Indicator | ROIV | AVB |
|---|---|---|
| Relative Strength Index (RSI) | 54.80 | 40.83 |
| Support Level | $33.01 | $174.68 |
| Resistance Level | $36.35 | $188.44 |
| Average True Range (ATR) | 1.26 | 3.47 |
| MACD | 0.04 | -0.83 |
| Stochastic Oscillator | 63.92 | 4.96 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About AVB AvalonBay Communities Inc.
AvalonBay Communities owns a portfolio of 296 apartment communities with more than 90,000 units and is developing 24 additional properties with approximately 8,600 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.